An Optimist’s Take on Funding Options for Small Biotechs
No, that’s not a typo. I’m feeling optimistic about fundraising opportunities for small biotechs. Yes, I know we’re seeing venture firms pull back on an almost weekly basis (Prospect Ventures, Scale...
View ArticleThe Small IPO: Not Dead Yet? Regulation A Debated
The biotech industry has long known it’s getting harder and harder for a small company to go public. As John Craighead, managing director of investor relations and business development for the...
View Article2010-12 Biotech IPOs Not Performing THAT Bad. Really.
What a difference two weeks makes. When I was researching last week’s BioWorld Insight cover – about how emerging biotech Verastem Inc., mature biotech Ironwood Pharmaceuticals Inc. and specialty...
View ArticleWhat Global Financial Crisis? Capital Markets Back Biotechs
It is that time of year again when we take the pulse of the industry at the close of the third quarter. Overall we find that it is performing well, more so for public biotechs than private ones....
View ArticleBubbleology and Biotech’s Bull Run
Our recent analysis of biotech’s second quarter performance showed, for public biotech companies at least, their bull run that began more than 18 months ago is showing no signs of slowing down. Since...
View Article
More Pages to Explore .....